FF 79 REGENCY

Episode 79

0:00-1:42:51

The Filtered Fragments (OG Filtrate) Joel Topf Jennie Lin Swapnil Hiremath Special Guest Brad Rovin GN God and second author from The Ohio State Koyal Jain GN Specialist from UNC Alfred Kim Rheumatologist from Washington University Editing by Simon Topf and Nayan Arora The Kidney Connection written and performed by by Tim Yau Show Notes Joel’s monologue One of the most surprising facts of nephrology is that despite conventional wisdom that lupus nephritis is an antibody mediated disease, that over a decade ago, the LUNAR investigtors were unable to find a significant benefit when rituximab was added to conventional therapy. And this was after the equally negative phase 2 trial of rituximab, EXPLORER. In fact, despite this finding rituximab has been able to burough its way into treatment of many nephrologists and rheumatologists as well as the KDIGO guidelines where it is suggested for patients with persistent disease activity or inadequate response to initial standard-of-care therapy. This long conflict is now coming to an end. Obinutuzumab, a newer, better monoclonal antibody targeting the same CD20 that we grew to love with rituximab, but it has a number of advantages. One. It is humanized antibody rather than a chimeric mouse-human antibody Two.

Publisher

Freely Filtered, a NephJC Podcast

Link

www.nephjc.com/freelyfiltered/2025/4/regency

Published

April 22, 2025

Duration

1h 43m

Format

Podcast

Category

Lifestyle · Medicine

Source

RSS feed

Host

NephJC Team

FF

Freely Filtered, a NephJC Podcast

@freelyfilteredanephjcpodcast

#regency #medicine

The Nile